IRadimed (IRMD) Stock Analysis & AI Equity Report
IRadimed (IRMD) overview
IRadimed (IRMD) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 83.8m and operating profit of USD 26.1m; the year-end share price was 97.28 USD and market capitalisation was USD 1,243m. IRadimed is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get IRadimed's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About IRadimed
IRadimed develops, manufactures, markets, and distributes medical devices and related products and services designed for use during magnetic resonance imaging procedures. Its portfolio includes MRI-compatible intravenous infusion pump systems, disposable tubing, mounting equipment, and remote displays, as well as a patient vital signs monitoring system. These products support clinicians caring for patients during MRI scans.
Generate the IRadimed report
IRadimed is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for IRadimed and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on IRadimed
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.